Mapping dopaminergic function using pharmacologic Magnetic Resonance Imaging (phMRI) in healthy subjects and users of amphetamine

Mapping dopaminergic function using pharmacologic Magnetic Resonance Imaging (phMRI) in healthy subjects and users of amphetamine - MPH-MRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33348

Enrollment

Registered

2009-10-27

Start date

2009-07-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drugsgebruik/verslaving brain damage neurotoxicity

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male. Between 18 and 35 years of age. Regular use of amphetamines (on more than 40 occasions the past year) for the amphetamine using group

Exclusion criteria

Exclusion criteria: Serious general medical condition or one that could interfere in the interpretation of results -use of (DA) medication within the last 2 weeks -excessive consumption of alcohol (>21 units/ week), caffeine (greater than eight cups of coffee per day) or cigarettes (greater than ten cigarettes per day). -Contraindications for MRI (e.g. osteosynthetic material, pacemaker, artificial cardiac valves), claustrophobia

Design outcomes

Primary

Measure	Time frame
Task related MRI: task related % change in BOLD and ASL signals. Task related phMRI: % change in BOLD and ASL signal after an oral methylphenidate challenge in task activated regions. Steady state phMRI: % change in BOLD and ASL signal from baseline after an oral methylphenidate challenge. SPECT: DAT ratio (striatal ROI binding/binding in cerebellum).	—

Secondary

Measure	Time frame
MRS: N-acetylasparate (NAA)/Creatine (Cr) ratio. DTI: fractional anisotropy (FA).	—

Countries

Netherlands

Outcome results